Gene regulation networks of dysfunctional immune responses in patients with ITP were constructed emphasizing the targeting of the resistin‐MIF axis and dysfunctional AA metabolism as potential avenues for the development of ITP treatment options. The gene discussed is RETN; the disease is autoimmune thrombocytopenic purpura.